Neurocrine uses option to licence rights to Idorsia’s inhibitor for treatment of rare children epilepsy

Neurocrine Biosciences has exercised its option to license the global rights to Idorsia’s ACT-709478, as it plans to initiate a Phase 2 study with this potent, selective, orally-active and brain penetrating T-type calcium channel blocker for the treatment of a rare pediatric epilepsy in the second half of 2020.

Read more

TopiVert’s gives dry eye syndrome candidate to first patient, waits results in second half of 2017

A UK-based private clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) for the treatment of chronic inflammatory gastrointestinal (GI) and ocular diseases, has triggered the phase 1/2a proof of concept study in the US of TOP1630 ophthalmic solution for the treatment of the dry eye syndrome.

Read more